- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | JPMorgan initiates TRex Bio stock coverage with overweight rating | 2 | Investing.com | ||
| Di | Stifel startet Coverage von TRex Bio mit "Buy" - Potenzial bei Treg-Therapien im Fokus | 1 | Investing.com Deutsch | ||
| Di | Stifel initiates TRex Bio stock coverage with buy rating on Treg therapy potential | 2 | Investing.com | ||
| 13.10. | TRexBio schließt Börsengang über 116,7 Millionen US-Dollar ab | 1 | Investing.com Deutsch | ||
| 13.10. | TRexBio completes $116.7 million initial public offering | 1 | Investing.com | ||
| 13.10. | TRex Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| TREX BIO Aktie jetzt für 0€ handeln | |||||
| 13.10. | TRex Bio, Inc.: TRexBio Announces Closing of Initial Public Offering | 1 | GlobeNewswire (USA) | ||
| 09.10. | Eli Lilly-backed TRex Bio closes day flat after IPO | 3 | Seeking Alpha | ||
| 09.10. | TRex Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 09.10. | Autoimmune and inflammatory diseases biotech TRex Bio prices IPO at $14, the low end of the range | 1 | Renaissance Capital | ||
| 09.10. | TRex Bio prices $117M IPO to support immune drug work | 1 | BioPharma Dive | ||
| 09.10. | Lilly-backed TRex Bio rakes in $117M IPO, while hypertension biotech Retension Pharma reveals $45M listing | 4 | FierceBiotech | ||
| 09.10. | Eli Lilly-backed TRexBio prices $117M US IPO at $14 per share | 2 | Seeking Alpha | ||
| 09.10. | TRex Bio Prices $116.7 Mln IPO At $14 Per Share | 809 | AFX News | INDIANAPOLIS (dpa-AFX) - TRex Bio, Inc. (TRXB), a clinical-stage biotechnology company developing immunoregulatory therapies for autoimmune and inflammatory diseases, has priced its initial... ► Artikel lesen | |
| 09.10. | TRexBio prices $117M IPO at $14 per share | 3 | Seeking Alpha | ||
| 09.10. | TRexBio Prices $116.7M IPO | 636 | AFX News | WASHINGTON (dpa-AFX) - Thursday, TRexBio announced the pricing of its initial public offering of 8.33 million shares at $14.00 per share, raising approximately $116.7 million in gross proceeds.The... ► Artikel lesen | |
| 09.10. | TRex Bio, Inc.: TRexBio Announces Pricing of Initial Public Offering | 332 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- TRex Bio, Inc. ("TRexBio") (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and... ► Artikel lesen | |
| 06.10. | TRex Bio, Inc. - 8-A12B, Registration of securities | - | SEC Filings | ||
| 06.10. | Eli Lilly-backed TRex Bio targets up to $133M in U.S. IPO | 4 | Seeking Alpha | ||
| 06.10. | TRex Bio eyes $111M IPO, as Retension Pharma and Lycia also look to Nasdaq | 5 | FierceBiotech |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,240 | +0,49 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Qiagen von 55 auf 53 US-Dollar gesenkt und die Aktien von "Overweight" auf "Equal Weight" abgestuft. Analyst Luke... ► Artikel lesen | |
| NURIX THERAPEUTICS | 15,330 | -40,63 % | Morning Market Movers: Curis, Inc., Darkiris, Amdocs, Nurix Therapeutics See Big Swings | NICOSIA (dpa-AFX) - At 8:05 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| MODERNA | 221,55 | +8,44 % | Kurssprung mit Ansage: Desert Gold Ventures und Oklo auf den Spuren von Moderna | Erstellt und veröffentlicht im Auftrag von Desert Gold Ventures. Moderna hat den großen Sprung bereits geschafft. Doch ausgerechnet die besten Studiendaten der Firmengeschichte schickten die Aktie auf... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 130,55 | +2,72 % | Oppenheimer raises Kymera Therapeutics price target on drug data | ||
| SUMMIT THERAPEUTICS | 15,760 | -0,25 % | Summit Therapeutics (NDQ:SMMT): The Company Bringing the First Bispecific Immunotherapy into Mainstream Lung Cancer | ||
| TARSUS PHARMACEUTICALS | 69,01 | -5,00 % | Tarsus Pharmaceuticals stock price target raised to $106 by H.C. Wainwright | ||
| VERA THERAPEUTICS | 31,900 | +3,88 % | Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026 | BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that there will be multiple presentations at the... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,600 | +2,99 % | Shandong Wit Dyne Health Co., Ltd. Profit Drops In Nine Months | ||
| BIONTECH | 80,55 | +3,80 % | Biontech mal wieder mit Plus - Gründer-Ehepaar vor Abschied | MAINZ (dpa-AFX) - Wenige Wochen vor dem angekündigten Abschied der Mitbegründer Ugur Sahin und Özlem Türeci hat Biontech einen Gewinn für das dritte Quartal gemeldet. Für die ersten neun Monate des... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 283,14 | +0,94 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,955 | +7,47 % | Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues | ||
| COGENT BIOSCIENCES | 31,410 | +1,06 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| ADMA BIOLOGICS | 11,310 | +1,71 % | ADMA Biologics, Inc.: ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026 | ||
| HARMONY BIOSCIENCES | 34,470 | -6,91 % | Harmony Biosciences Holdings Q3 2026 Earnings Call Transcript | ||
| KINIKSA PHARMACEUTICALS | 94,44 | +1,23 % | Goldman Sachs raises Kiniksa stock price target on strong Arcalyst sales |
Das Unternehmen TREX BIO INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,160 (-1,19 %) liegt der Kurs bei 13,250 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TREX BIO INC finden Sie auf Wallstreet Online.